
## Sudarshan Paramsothy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6748870/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 246-255.	1.4	22
2	Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 141-151.	3.7	104
3	Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210807.	1.4	10
4	Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply. The Lancet Gastroenterology and Hepatology, 2022, 7, 286-287.	3.7	1
5	Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease. World Journal of Gastroenterology, 2022, 28, 2597-2608.	1.4	8
6	Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy. Gut, 2021, 70, 2210-2211.	6.1	12
7	Review of pregnancy in Crohn's disease and ulcerative colitis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110162.	1.4	19
8	High prevalence of Crohn disease and ulcerative colitis among older people in Sydney. Medical Journal of Australia, 2021, 214, 365-370.	0.8	10
9	Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection. MSystems, 2021, 6, .	1.7	16
10	Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opinion on Drug Safety, 2021, 20, 275-292.	1.0	24
11	Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. BMJ Open, 2021, 11, e042493.	0.8	6
12	Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2021, 33, 1524-1532.	0.8	6
13	Travel risk management. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 32-33.	1.4	0
14	680 LYOPHILIZED ORALLY ADMINISTERED FECAL MICROBIOTA TRANSPLANTATION IN THE MANAGEMENT OF ULCERATIVE COLITIS (LOTUS STUDY) – RESULTS FROM THE INDUCTION PHASE OF A RANDOMIZED CONTROLLED TRIAL. Gastroenterology, 2021, 160, S-135.	0.6	2
15	Combination Therapy of Immunomodulators With Non–Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	Ο
16	Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with antiâ€TNF biological agents: realâ€world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Alimentary Pharmacology and Therapeutics, 2021, 54, 292-301.	1.9	39
17	Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2021, Publish Ahead of Print, .	0.2	11
18	Promise of Fecal Microbiota Transplantation Therapy in Pouchitis. Digestive Diseases and Sciences, 2020, 65, 1107-1110.	1.1	5

#	Article	IF	CITATIONS
19	Faecal microbiota transplantation as an elixir of youth. Hepatobiliary Surgery and Nutrition, 2020, 9, 488-489.	0.7	0
20	The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease. Current Opinion in Pharmacology, 2020, 55, 8-16.	1.7	22
21	Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey. European Journal of Gastroenterology and Hepatology, 2020, 32, 976-983.	0.8	9
22	Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for †leaky-gut' in inflammatory bowel disease. Scientific Reports, 2020, 10, 12932.	1.6	13
23	Defined microbiota transplant restores Th17/RORÎ <sup>3</sup> t <sup>+</sup> regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21536-21545.	3.3	58
24	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut, 2020, 69, 801-810.	6.1	52
25	Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. Cell Host and Microbe, 2020, 27, 823-829.e3.	5.1	110
26	Reply. Gastroenterology, 2019, 157, 1165-1166.	0.6	1
27	Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. International Journal of Colorectal Disease, 2019, 34, 1771-1779.	1.0	16
28	Safety of drugs used for the treatment of Crohn's disease. Expert Opinion on Drug Safety, 2019, 18, 357-367.	1.0	29
29	Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology, 2019, 156, 1440-1454.e2.	0.6	290
30	Epidemiology of inflammatory bowel disease in South America: A systematic review. World Journal of Gastroenterology, 2019, 25, 6866-6875.	1.4	30
31	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunology, 2018, 11, 1558-1570.	2.7	80
32	Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet, The, 2017, 389, 1218-1228.	6.3	908
33	Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2017, 11, 1180-1199.	0.6	323
34	Ten-Year Retained Video Capsule With Crohn's-Associated Small-Bowel Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2017, 15, A29-A30.	2.4	1
35	Review article: acute severe ulcerative colitis – evidenceâ€based consensus statements. Alimentary Pharmacology and Therapeutics, 2016, 44, 127-144.	1.9	63
36	The Role of Biosimilars in Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2016, 12, 741-751.	0.2	6

#	Article	IF	CITATIONS
37	Donor Recruitment for Fecal Microbiota Transplantation. Inflammatory Bowel Diseases, 2015, 21, 1600-1606.	0.9	122
38	Gastroenterologist perceptions of faecal microbiota transplantation. World Journal of Gastroenterology, 2015, 21, 10907.	1.4	33
39	Therapeutic faecal microbiota transplantation. Current Opinion in Gastroenterology, 2014, 30, 97-105.	1.0	101
40	Is Crohn's Disease Ready for Fecal Microbiota Transplantation?. Journal of Clinical Gastroenterology, 2014, 48, 582-583.	1.1	11
41	Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions. Current Gastroenterology Reports, 2013, 15, 337.	1.1	210
42	Fecal microbiota transplantation: a new standard treatment option for <i>Clostridium difficile</i> infection. Expert Review of Anti-Infective Therapy, 2013, 11, 447-449.	2.0	21
43	Anorectal Lesion in a Middle-Aged Woman. Gastroenterology, 2012, 142, e1-e2.	0.6	0
44	Fluorescein contrast in confocal laser endomicroscopy. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 366-368.	8.2	23
45	Resumption of oral intake following percutaneous endoscopic gastrostomy. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1098-1101.	1.4	8